Scpharmaceuticals Inc (SCPH) - Net Assets
Based on the latest financial reports, Scpharmaceuticals Inc (SCPH) has net assets worth $-21.32 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($80.25 Million) and total liabilities ($101.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SCPH asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-21.32 Million |
| % of Total Assets | -26.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | -83.79% |
| 10-Year Change | N/A |
| Growth Volatility | 41.05 |
Scpharmaceuticals Inc - Net Assets Trend (2015–2024)
This chart illustrates how Scpharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore SCPH total assets for the complete picture of this company's asset base.
Annual Net Assets for Scpharmaceuticals Inc (2015–2024)
The table below shows the annual net assets of Scpharmaceuticals Inc from 2015 to 2024. For live valuation and market cap data, see SCPH market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $13.32 Million | -64.21% |
| 2023-12-31 | $37.22 Million | -48.62% |
| 2022-12-31 | $72.43 Million | +28.27% |
| 2021-12-31 | $56.47 Million | -31.28% |
| 2020-12-31 | $82.17 Million | +59.97% |
| 2019-12-31 | $51.37 Million | -34.77% |
| 2018-12-31 | $78.74 Million | -25.71% |
| 2017-12-31 | $106.00 Million | +385.91% |
| 2016-12-31 | $-37.07 Million | -103.26% |
| 2015-12-31 | $-18.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scpharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34767200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.04% |
| Other Components | $379.81 Million | 2851.42% |
| Total Equity | $13.32 Million | 100.00% |
Scpharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Scpharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rimini Street Inc
NASDAQ:RMNI
|
$304.38 Million |
|
P.C.B Tec
TA:PCBT
|
$304.47 Million |
|
Kogeneracja SA
WAR:KGN
|
$304.68 Million |
|
Antipa Minerals Ltd
AU:AZY
|
$304.70 Million |
|
Rxsight Inc
NASDAQ:RXST
|
$304.26 Million |
|
Ratos AB (publ)
ST:RATO-A
|
$304.22 Million |
|
TYC Brother Industrial Co Ltd
TW:1522
|
$304.19 Million |
|
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
|
$304.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scpharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 37,218,000 to 13,320,000, a change of -23,898,000 (-64.2%).
- Net loss of 85,148,000 reduced equity.
- New share issuances of 53,547,000 increased equity.
- Other comprehensive income increased equity by 1,000.
- Other factors increased equity by 7,702,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-85.15 Million | -639.25% |
| Share Issuances | $53.55 Million | +402.0% |
| Other Comprehensive Income | $1.00K | +0.01% |
| Other Changes | $7.70 Million | +57.82% |
| Total Change | $- | -64.21% |
Book Value vs Market Value Analysis
This analysis compares Scpharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 18.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-1.63 | $5.67 | x |
| 2016-12-31 | $-3.31 | $5.67 | x |
| 2017-12-31 | $35.78 | $5.67 | x |
| 2018-12-31 | $4.24 | $5.67 | x |
| 2019-12-31 | $2.76 | $5.67 | x |
| 2020-12-31 | $3.34 | $5.67 | x |
| 2021-12-31 | $2.06 | $5.67 | x |
| 2022-12-31 | $2.55 | $5.67 | x |
| 2023-12-31 | $0.97 | $5.67 | x |
| 2024-12-31 | $0.30 | $5.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scpharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -639.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -234.36%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 8.07x
- Recent ROE (-639.25%) is below the historical average (-105.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.69 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.67 Million |
| 2017 | -22.47% | 0.00% | 0.00x | 1.15x | $-34.42 Million |
| 2018 | -37.39% | 0.00% | 0.00x | 1.19x | $-37.32 Million |
| 2019 | -67.00% | 0.00% | 0.00x | 1.50x | $-39.55 Million |
| 2020 | -39.20% | 0.00% | 0.00x | 1.33x | $-40.43 Million |
| 2021 | -49.64% | 0.00% | 0.00x | 1.40x | $-33.68 Million |
| 2022 | -50.86% | -1785.65% | 0.02x | 1.71x | $-44.08 Million |
| 2023 | -147.27% | -403.22% | 0.14x | 2.54x | $-58.53 Million |
| 2024 | -639.25% | -234.36% | 0.34x | 8.07x | $-86.48 Million |
Industry Comparison
This section compares Scpharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scpharmaceuticals Inc (SCPH) | $-21.32 Million | 0.00% | N/A | $304.36 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more